Abstract:Background: Many studies showed disrupted tryptophan metabolism in patients with affective disorders. The aims of this study were to explore the differences in the metabolites of tryptophan pathway (TP) and the relationships between TP metabolites and clinical symptoms, therapeutic effect in patients with bipolar disorder with acute manic episode (BD-M), depressive episode (BD-D) and major depressive disorder (MDD). Methods: Patients with BD-M (n=52) and BD-D (n=39), MDD (n=48) and healthy controls (HCs, n=49) were enrolled. The serum neuroactive metabolites levels of the TP were measured by liquid chromatography-tandem mass spectrometry. Hamilton Depression Scale-17 item (HAMD-17) and Young Mania Rating Scale (YMRS) were used to evaluate depressive and manic symptoms at baseline and after 8 weeks of antidepressants, mood stabilizers, some also received antipsychotic medication. Results: The levels of tryptophan (TRP) and kynurenic acid (KYNA) were significantly lower and the ratios of tryptophan/kynurenine (TRP/KYN), 5-hydroxytryptamine/tryptophan (5-HT/TRP), quinolinic acid/kynurenic acid (QUIN/KYNA) were higher in BD-M, BD-D, MDD vs. HC. The levels of QUIN and the ratios of QUIN/KYNA were higher in BD-M than in BD-D, MDD, and HCs. The 5-hydroxyindoleacetic acid (5-HIAA) levels of patients with MDD were significantly higher than those in BD-M and BD-D. Binary logistic regression analysis showed the lower peripheral KYNA, the higher the QUIN level, and the higher the risk of BD-M; the lower peripheral KYNA and the higher KYN/TRP and 5-HT/TRP, the higher the risk of BD-D; and the lower the peripheral KYNA level and the higher the KYN/TRP and 5-HT/TRP, the higher the risk of MDD. Correlation analysis, showing a significant association between tryptophan metabolites and improvement of clinical symptoms, especially depression symptoms. Conclusions: Patients with affective disorders had abnormal tryptophan metabolism, which involved in 5-HT and kynurenine pathway (KP) sub-pathway. Tryptophan metabolites might be potential biomarkers for affective disorders and some metabolites have been associated with remission of depressive symptoms.

Serum Metabolomic Profiling Revealed Potential Diagnostic Biomarkers in Patients with Panic Disorder

Direct and rapid detection of serum amino acid and monoamine neurotransmitters to assist the diagnosis of panic disorder

Serum metabolomics study of anxiety disorder patients based on LC-MS

Untargeted Metabolomics Analysis in Drug-Naive Patients with Severe Obsessive-Compulsive Disorder

A Panel of Mirnas is Involved in the Effect of Sertraline on Panic Disorder, As Implicated by a Microarray-Based Analysis

Leptin, Nesfatin-1, Orexin-A, and Total Ghrelin Levels in Drug-Naive Panic Disorder

Integrated genome-wide methylation and expression analyses provide predictors of diagnosis and early response to antidepressant in panic disorder

Metabolomics profiling reveals altered lipid metabolism and identifies a panel of lipid metabolites as biomarkers for Parkinson’s disease related anxiety disorder

Biomarkers in Panic Disorder

Search for serum biomarkers in patients with bipolar disorder and major depressive disorder using metabolome analysis

Non-targeted Metabolomics Profiling of Plasma Samples From Patients With Major Depressive Disorder

The Relationship of Peripheral Blood Single Uncoding RNA-25-3p Expression Level and the Sertraline Efficacy in Patients with Panic Disorder

Pilot Study of Genome-Wide DNA Methylation and Gene Expression for Treatment Response to Escitalopram in Panic Disorder.

Metabolomic analysis to detect urinary molecular changes associated with bipolar depression

Serum metabolomics of end-stage renal disease patients with depression: potential biomarkers for diagnosis

Identification of Proline, 1-Pyrroline-5-carboxylate and Glutamic Acid As Biomarkers of Depression Reflecting Brain Metabolism Using Carboxylomics, a New Metabolomics Method

Breaking the Fear Barrier: Aberrant Activity of Fear Networks as a Prognostic Biomarker in Patients with Panic Disorder Normalized by Pharmacotherapy

Polyunsaturated fatty acids metabolism, purine metabolism and inosine as potential independent diagnostic biomarkers for major depressive disorder in children and adolescents

Serum neuroactive metabolites of the tryptophan pathway in patients with acute phase of affective disorders

Poster #M76 AN OPEN-LABEL, FLEXIBLE-DOSE STUDY OF PALIPERIDONE EXTENDED RELEASE IN CHINESE PATIENTS WITH FIRST-ONSET PSYCHOSIS

Effects of antidepressant on FKBP51 mRNA expression and neuroendocrine hormones in patients with panic disorder